225526-17-0
| 中文名称 | 225526-17-0 |
|---|---|
| 中文同义词 | SUBSTANCE P RECEPTOR ANTAGONIST 1;化合物 T10121;化合物 SUBSTANCE P RECEPTOR ANTAGONIST 1 |
| 英文名称 | 3-Piperidinamine, N-[[3,4-dihydro-6-methoxy-1-methyl-1-(trifluoromethyl)-1H-2-benzopyran-7-yl]methyl]-2-phenyl-, (2S,3S)- |
| 英文同义词 | Substance P Receptor Antagonist 1;3-Piperidinamine, N-[[3,4-dihydro-6-methoxy-1-methyl-1-(trifluoromethyl)-1H-2-benzopyran-7-yl]methyl]-2-phenyl-, (2S,3S)- |
| CAS号 | 225526-17-0 |
| 分子式 | C24H29F3N2O2 |
| 分子量 | 434.4944696 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 225526-17-0.mol |
| 结构式 |  |
225526-17-0 性质
| 沸点 | 511.0±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.23±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 9.15±0.10(Predicted) |
Substance P Receptor Antagonist 1 在中枢神经系统疾病，呼吸疾病和炎症以及肠胃失调等方面具有潜在的作用。
Substance P Receptor Antagonist 1 has the potential function in numerous diseases, including central nervous system disorders such as depression, anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, in gastrointestinal disorders and diseases of the GI tract such as ulcerative colitis and Crohn's disease, and in the transmission of pain, including migraine.